Lifecore Biomedical (NASDAQ:LFCR) Issues Quarterly Earnings Results

Lifecore Biomedical (NASDAQ:LFCR) issued its earnings results on Thursday. The company reported ($0.19) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.05), Zacks reports. The company had revenue of $35.15 million during the quarter, compared to analysts’ expectations of $33.23 million. Lifecore Biomedical had a negative net margin of 12.52% and a negative return on equity of 315.23%. Lifecore Biomedical updated its FY 2025 guidance to EPS.

Lifecore Biomedical Trading Down 5.4 %

Shares of LFCR opened at $6.81 on Friday. The company has a debt-to-equity ratio of 9.21, a current ratio of 2.32 and a quick ratio of 1.21. Lifecore Biomedical has a 1-year low of $3.68 and a 1-year high of $7.99. The stock has a market cap of $252.14 million, a price-to-earnings ratio of -12.16 and a beta of 0.96. The firm has a 50 day simple moving average of $6.19 and a 200-day simple moving average of $6.24.

Analyst Ratings Changes

Separately, Stephens restated an “equal weight” rating and issued a $6.00 price target on shares of Lifecore Biomedical in a research report on Friday, January 3rd.

Insider Activity at Lifecore Biomedical

In related news, CEO Paul Josephs acquired 17,000 shares of the company’s stock in a transaction that occurred on Wednesday, January 8th. The stock was purchased at an average price of $5.74 per share, for a total transaction of $97,580.00. Following the transaction, the chief executive officer now owns 559,717 shares in the company, valued at $3,212,775.58. This trade represents a 3.13 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 32.20% of the stock is owned by corporate insiders.

About Lifecore Biomedical

Lifecore Biomedical, Inc, together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures.